Update on Chronic Hepatitis B

Vinod Rustgi, Damaris Carriero, Michelle Bachtold, Gillian Zeldin

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Chronic hepatitis B virus (HBV) infection affects over 350 million people worldwide and over 1 million die annually of HBV-related chronic liver disease. The prolonged immunologic response to HBV infection leads to the development of cirrhosis, liver failure, or hepatocellular carcinoma (HCC) in up to 40% of patients. The implementation of mass immunization programs has dramatically decreased the incidence of HBV infection among infants, children, and adolescents in many countries, but there remains a large number who were infected with HBV before such programs. A variety of host, viral, and external factors influence HBV disease progression and the risk of chronic infection. Six drugs are currently FDA-approved for the treatment of chronic HBV infection. While novel antiviral drugs have improved the management of cirrhosis, strategies to prevent and treat HCC remain inadequate.

Original languageEnglish (US)
Pages (from-to)631-639
Number of pages9
JournalJournal for Nurse Practitioners
Issue number8
StatePublished - Sep 2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Advanced and Specialized Nursing


  • Chronic HBV infection
  • Cirrhosis
  • Hepatitis B
  • Hepatocellular carcinoma
  • Interferon


Dive into the research topics of 'Update on Chronic Hepatitis B'. Together they form a unique fingerprint.

Cite this